Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance).

Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR.

Oncologist. 2019 Dec 24. doi: 10.1634/theoncologist.2019-0574. [Epub ahead of print]

2.

Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.

Roden AC, Fang W, Shen Y, Carter BW, White DB, Jenkins SM, Spears GM, Molina JR, Klang E, Segni MD, Ackman JB, Sanchez EZ, Girard N, Shumeri E, Revel MP, Chassagnon G, Rubinowitz A, Dicks D, Detterbeck F, Ko JP, Falkson CB, Sigurdson S, Segreto S, Vecchio SD, Palmieri G, Ottaviano M, Marino M, Korst R, Marom EM.

J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33848-1. doi: 10.1016/j.jtho.2019.12.108. [Epub ahead of print]

PMID:
31870881
3.

Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer.

McCleary-Wheeler AL, Carr RM, Palmer SR, Smyrk TC, Allred JB, Almada LL, Tolosa EJ, Lamberti MJ, Marks DL, Borad MJ, Molina JR, Qi Y, Lingle WL, Grothey A, Pitot HC, Jatoi A, Northfelt DW, Bryce AH, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G, Lowe VJ, Callstrom MR, Ma WW, Bekaii-Saab T, Hung MC, Erlichman C, Fernandez-Zapico ME.

Pancreatology. 2020 Jan;20(1):101-109. doi: 10.1016/j.pan.2019.11.011. Epub 2019 Nov 21.

PMID:
31787526
4.

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study.

Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, Nieva JJ, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR.

J Thorac Oncol. 2020 Jan;15(1):110-119. doi: 10.1016/j.jtho.2019.09.083. Epub 2019 Oct 9.

PMID:
31605793
5.

PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses.

Sarkar Bhattacharya S, Thirusangu P, Jin L, Roy D, Jung D, Xiao Y, Staub J, Roy B, Molina JR, Shridhar V.

Cell Death Dis. 2019 Sep 27;10(10):725. doi: 10.1038/s41419-019-1916-3.

6.

Characterisation of induced abortion and consequences to women's health at Hospital Central do Huambo - Angola.

de Almeida N, Teixeira A, Capoco Sachiteque A, Molina JR, Dos Prazeres Tavares H, Ramalho C.

J Obstet Gynaecol. 2019 Sep 1:1-6. doi: 10.1080/01443615.2019.1635096. [Epub ahead of print]

PMID:
31475598
7.

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.

Duma N, Santana-Davila R, Molina JR.

Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. Review.

PMID:
31378236
8.

Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.

Russell SJ, Babovic-Vuksanovic D, Bexon A, Cattaneo R, Dingli D, Dispenzieri A, Deyle DR, Federspiel MJ, Fielding A, Galanis E, Lacy MQ, Leibovich BC, Liu MC, Muñoz-Alía M, Miest TC, Molina JR, Mueller S, Okuno SH, Packiriswamy N, Peikert T, Raffel C, Van Rhee F, Ungerechts G, Young PR, Zhou Y, Peng KW.

Mayo Clin Proc. 2019 Sep;94(9):1834-1839. doi: 10.1016/j.mayocp.2019.05.006. Epub 2019 Jun 22. Review.

9.

Wildfires impact on the economic susceptibility of recreation activities: Application in a Mediterranean protected area.

Molina JR, González-Cabán A, Rodríguez Y Silva F.

J Environ Manage. 2019 Sep 1;245:454-463. doi: 10.1016/j.jenvman.2019.05.131. Epub 2019 Jun 3.

PMID:
31170634
10.

The role of flagship species in the economic valuation of wildfire impacts: An application to two Mediterranean protected areas.

Molina JR, Zamora R, Rodríguez Y Silva F.

Sci Total Environ. 2019 Jul 20;675:520-530. doi: 10.1016/j.scitotenv.2019.04.242. Epub 2019 Apr 19.

PMID:
31030158
11.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML.

JAMA Oncol. 2019 Jul 1;5(7):1008-1019. doi: 10.1001/jamaoncol.2019.0393.

PMID:
31021376
12.

Socioecological system and potential deforestation in Western Amazon forest landscapes.

Bonilla-Bedoya S, Estrella-Bastidas A, Molina JR, Herrera MÁ.

Sci Total Environ. 2018 Dec 10;644:1044-1055. doi: 10.1016/j.scitotenv.2018.07.028. Epub 2018 Jul 11.

PMID:
30743818
13.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

14.

Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion.

Ren H, Hou X, Eiken PW, Zhang J, Pierson KE, Nair AA, Davila JI, Kovarikova H, Jang JS, Johnson SH, Molina JR, Marks RS, Yang P, Yi JE, Mansfield AS, Jen J.

Clin Lung Cancer. 2019 Mar;20(2):e142-e147. doi: 10.1016/j.cllc.2018.11.002. Epub 2018 Nov 20. No abstract available.

PMID:
30581091
15.

Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

Duma N, Kothadia SM, Azam TU, Yadav S, Paludo J, Vera Aguilera J, Gonzalez Velez M, Halfdanarson TR, Molina JR, Hubbard JM, Go RS, Mansfield AS, Adjei AA.

Oncologist. 2019 Jan;24(1):96-102. doi: 10.1634/theoncologist.2017-0687. Epub 2018 Nov 9.

16.

Carcinoid Heart Disease in Patients With Bronchopulmonary Carcinoid.

De Jesus T, Luis SA, Ryu JH, Molina JR, Connolly HM, Maleszewski JJ, Pellikka PA.

J Thorac Oncol. 2018 Oct;13(10):1602-1605. doi: 10.1016/j.jtho.2018.06.023. Epub 2018 Jul 7.

17.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.

Nat Med. 2018 Jul;24(7):1036-1046. doi: 10.1038/s41591-018-0052-4. Epub 2018 Jun 11.

PMID:
29892070
18.

BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.

Lee HE, Molina JR, Sukov WR, Roden AC, Yi ES.

Hum Pathol. 2018 Sep;79:168-176. doi: 10.1016/j.humpath.2018.05.001. Epub 2018 May 12.

PMID:
29763720
19.

Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424).

Cheng TD, Darke AK, Redman MW, Zirpoli GR, Davis W, Payne Ondracek R, Bshara W, Omilian AR, Kratzke R, Reid ME, Molina JR, Kolesar JM, Chen Y, MacRae RM, Moon J, Mack P, Gandara DR, Kelly K, Santella RM, Albain KS, Ambrosone CB.

J Natl Cancer Inst. 2018 Jul 1;110(7):734-742. doi: 10.1093/jnci/djx260.

20.

Editorial: pleural recurrence of thymoma-what is the value of intra-thoracic chemo-hyperthermia?

Roden AC, Molina JR.

J Thorac Dis. 2017 Oct;9(10):3583-3586. doi: 10.21037/jtd.2017.09.44. No abstract available.

21.

Economic susceptibility of fire-prone landscapes in natural protected areas of the southern Andean Range.

Molina JR, Moreno R, Castillo M, Rodríguez Y Silva F.

Sci Total Environ. 2018 Apr 1;619-620:1557-1565. doi: 10.1016/j.scitotenv.2017.11.233. Epub 2017 Dec 6.

PMID:
29221619
22.

A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness.

Yan F, Shen N, Pang J, Zhao N, Deng B, Li B, Yang Y, Yang P, Molina JR, Liu S.

Oncogene. 2017 Dec 14;36(50):6919-6928. doi: 10.1038/onc.2017.305. Epub 2017 Sep 4.

23.

Prescribed fire experiences on crop residue removal for biomass exploitations. Application to the maritime pine forests in the Mediterranean Basin.

Molina JR, García JP, Fernández JJ, Rodríguez Y Silva F.

Sci Total Environ. 2018 Jan 15;612:63-70. doi: 10.1016/j.scitotenv.2017.08.182. Epub 2017 Sep 1.

PMID:
28846905
24.

Management of Multifocal Lung Cancer: Results of a Survey.

Leventakos K, Peikert T, Midthun DE, Molina JR, Blackmon S, Nichols FC, Garces YI, Hallemeier CL, Murphy SJ, Vasmatzis G, Kratz SL, Holland WP, Thomas CF, Mullon JJ, Shen KR, Cassivi SD, Marks RS, Aubry MC, Adjei AA, Yang P, Allen MS, Edell ES, Wigle D, Mansfield AS.

J Thorac Oncol. 2017 Sep;12(9):1398-1402. doi: 10.1016/j.jtho.2017.05.013. Epub 2017 Jun 3.

25.

digit-a tool for detection and identification of genomic interchromosomal translocations.

Meier R, Graw S, Beyerlein P, Koestler D, Molina JR, Chien J.

Nucleic Acids Res. 2017 May 19;45(9):e72. doi: 10.1093/nar/gkx010.

26.

A system to evaluate fire impacts from simulated fire behavior in Mediterranean areas of Central Chile.

Castillo ME, Molina JR, Rodríguez Y Silva F, García-Chevesich P, Garfias R.

Sci Total Environ. 2017 Feb 1;579:1410-1418. doi: 10.1016/j.scitotenv.2016.11.139. Epub 2016 Dec 4.

PMID:
27923572
27.

Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.

Yan F, Pang J, Peng Y, Molina JR, Yang P, Liu S.

PLoS One. 2016 Sep 9;11(9):e0162925. doi: 10.1371/journal.pone.0162925. eCollection 2016.

28.

Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis.

Jinesh GG, Molina JR, Huang L, Laing NM, Mills GB, Bar-Eli M, Kamat AM.

Cell Death Discov. 2016 Feb 1;2:16003. doi: 10.1038/cddiscovery.2016.3. eCollection 2016.

29.

A genetic cell context-dependent role for ZEB1 in lung cancer.

Zhang T, Guo L, Creighton CJ, Lu Q, Gibbons DL, Yi ES, Deng B, Molina JR, Sun Z, Yang P, Yang Y.

Nat Commun. 2016 Jul 26;7:12231. doi: 10.1038/ncomms12231.

30.

c-Met expression and MET amplification in malignant pleural mesothelioma.

Bois MC, Mansfield AS, Sukov WR, Jenkins SM, Moser JC, Sattler CA, Smith CY, Molina JR, Peikert T, Roden AC.

Ann Diagn Pathol. 2016 Aug;23:1-7. doi: 10.1016/j.anndiagpath.2016.04.007. Epub 2016 Apr 30.

PMID:
27402216
31.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

32.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

33.

DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.

Alam SK, Yadav VK, Bajaj S, Datta A, Dutta SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA, Smyrk TC, Molina JR, Chakrabarti S, Chowdhury S, Mukhopadhyay D, Roychoudhury S.

Cell Death Differ. 2016 Apr;23(4):707-22. doi: 10.1038/cdd.2015.133. Epub 2015 Oct 23.

34.

RESPONSE OF UVEAL METASTASES TO ALK INHIBITORS IN ALK-POSITIVE NON-SMALL-CELL LUNG CANCER.

Abdellatief A, Molina JR, Pulido JS.

Retin Cases Brief Rep. 2016 Winter;10(1):37-40. doi: 10.1097/ICB.0000000000000190.

PMID:
26263240
35.

The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells.

Yan F, Shen N, Pang J, Molina JR, Yang P, Liu S.

J Biol Chem. 2015 Jul 24;290(30):18480-94. doi: 10.1074/jbc.M114.633693. Epub 2015 Jun 17.

36.

Pulmonary Artery Agenesis Associated With Emphysema and Multiple Invasive Non-Small Cell Lung Cancers.

Makdisi G, Edell ES, Maleszewski JJ, Molina JR, Deschamps C.

Ann Thorac Surg. 2015 Jun;99(6):2192-5. doi: 10.1016/j.athoracsur.2014.08.062.

PMID:
26046873
37.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer.

Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, Pandya SS, Millham R, Borzillo G, Pierce KJ, Han L, Houk BE, Gallo JD, Alsina M, Braña I, Tabernero J.

Clin Cancer Res. 2015 Apr 15;21(8):1888-95. doi: 10.1158/1078-0432.CCR-14-1306. Epub 2015 Feb 4.

38.

A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.

Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM Jr, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD 3rd, Aubry MC, Adjei AA.

J Thorac Oncol. 2015 Jan;10(1):172-80. doi: 10.1097/JTO.0000000000000383.

39.

Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.

Hoeppner LH, Wang Y, Sharma A, Javeed N, Van Keulen VP, Wang E, Yang P, Roden AC, Peikert T, Molina JR, Mukhopadhyay D.

Mol Oncol. 2015 Jan;9(1):270-81. doi: 10.1016/j.molonc.2014.08.008. Epub 2014 Aug 30.

40.

Restoration of miR-101 suppresses lung tumorigenesis through inhibition of DNMT3a-dependent DNA methylation.

Yan F, Shen N, Pang J, Xie D, Deng B, Molina JR, Yang P, Liu S.

Cell Death Dis. 2014 Sep 11;5:e1413. doi: 10.1038/cddis.2014.380.

41.

NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.

Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA.

J Thorac Oncol. 2014 Aug;9(8):1146-53. doi: 10.1097/JTO.0000000000000217.

42.

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J, Adjei AA.

Lung Cancer. 2014 Aug;85(2):245-50. doi: 10.1016/j.lungcan.2014.03.004. Epub 2014 May 1.

43.

Modelling available crown fuel for Pinus pinaster Ait. stands in the "Cazorla, Segura and Las Villas Natural Park" (Spain).

Molina JR, Rodríguez y Silva F, Mérida E, Herrera MÁ.

J Environ Manage. 2014 Nov 1;144:26-33. doi: 10.1016/j.jenvman.2014.05.003. Epub 2014 Jun 6.

PMID:
24908612
44.

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium.

J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25.

45.

Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.

Geiger JL, Lazim AF, Walsh FJ, Foote RL, Moore EJ, Okuno SH, Olsen KD, Kasperbauer JL, Price DL, Garces YI, Ma DJ, Neben-Wittich MA, Molina JR, Garcia JJ, Price KA.

Oral Oncol. 2014 Apr;50(4):311-8. doi: 10.1016/j.oraloncology.2014.01.001. Epub 2014 Jan 24.

PMID:
24467937
46.

NUT midline carcinoma: an aggressive intrathoracic neoplasm.

Parikh SA, French CA, Costello BA, Marks RS, Dronca RS, Nerby CL, Roden AC, Peddareddigari VG, Hilton J, Shapiro GI, Molina JR.

J Thorac Oncol. 2013 Oct;8(10):1335-8. doi: 10.1097/JTO.0b013e3182a00f41.

47.

Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis.

Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, Miller RC.

J Hum Genet. 2014 Mar;59(3):124-8. doi: 10.1038/jhg.2013.132. Epub 2013 Dec 26.

48.

Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer.

Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR.

Anticancer Drugs. 2013 Nov;24(10):1079-83. doi: 10.1097/CAD.0000000000000009.

49.

Morphology and morphometric relationships of the sagitta of Diapterus auratus (Perciformes: Gerreidae) from Veracruz, Mexico.

Félix VR, Martínez-Pérez JA, Molina JR, Emiliano R, Zuñiga Q, López JF.

Rev Biol Trop. 2013 Mar;61(1):139-47.

PMID:
23894968
50.

Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.

Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB.

Clin Cancer Res. 2013 Jul 1;19(13):3703-13. doi: 10.1158/1078-0432.CCR-13-0623. Epub 2013 May 22.

Supplemental Content

Loading ...
Support Center